Kolexia
Stamatoullas Aspasia Hématologie
Stamatoullas Aspasia
Hématologie
Centre Henri-Becquerel
Rouen, France
237 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Syndromes myélodysplasiques Leucémies Lymphome B Leucémie aigüe myéloïde Lymphome B diffus à grandes cellules Préleucémie Anémie

Collaborateurs

Voir plus
Fenaux Pierre
Fenaux Pierre
Hôpital Saint-Louis, Paris, France
Ades Lionel
Ades Lionel
Hôpital Saint-Louis, Paris, France
Jardin Fabrice
Jardin Fabrice
Centre Henri-Becquerel, Rouen, France
Rauzy Odile
Rauzy Odile
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

Industries

Voir plus
Janssen
10 collaboration(s)
Dernière en 2023
Pfizer
5 collaboration(s)
Dernière en 2021
Takeda Pharmaceutical
3 collaboration(s)
Dernière en 2023
Abbvie
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma: Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   21 février 2024
AVENHIR: Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Abbvie)   02 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024
A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)
65th ASH Annual Meeting Abstracts   02 novembre 2023
Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Correction to: Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B‑cell lymphoma: results of a multicentric prospective cohort study.
Annals of hematology   26 octobre 2023
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes: A Phase I/II, Open-label, Single Arm, Multicenter Dose-finding Study Assess the Safety and Preliminary Efficacy of Oral Azacitidine CC-486 (ONUREG) in Combination With Venetoclax (VENCLYXTO) in Previously Untreated Higher-risk Myelodysplastic Syndromes Ineligible for Allogenic Transplantation
Essai Clinique (BMS)   25 octobre 2023
Venetoclax in Patients With MDS or AML in Relapse After AHSCT: A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML (Blasts < 30%) in Relapse After Allohematopoietic Stem Cell Transplantation
Essai Clinique (Abbvie)   12 septembre 2023
Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report.
Clinical case reports   23 juin 2023
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock
Proceedings of Reanimation 2023, the French Intensive Care Society International Congress   14 juin 2023